Nina Novakovic
Physician Assistant · Chandler, AZNPI 1124503909
Payments from drug & device makers
Across 357 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$966
- Eisai Inc.$355
- Johnson & Johnson$319
- Novo Nordisk$201
- Boehringer Ingelheim$194
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,43299%
- Education$190%
- Entertainment$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 172 | $1,680 |
| AstraZeneca | 21 | $966 |
| Eisai Inc. | 12 | $355 |
| Johnson & Johnson(2 entities) | 27 | $319 |
| Novo Nordisk | 12 | $201 |
| Boehringer Ingelheim | 10 | $194 |
| Lilly USA, LLC | 12 | $179 |
| Amarin Pharma, Inc. | 13 | $155 |
| Nestle Healthcare Nutrition Inc. | 10 | $155 |
| GSK | 7 | $126 |
| Abbott | 5 | $117 |
| Boston Scientific | 6 | $108 |
| Pfizer | 5 | $93 |
| Lucid Diagnostics Inc. | 5 | $85 |
| Kowa Pharmaceuticals America, Inc. | 5 | $74 |
| Aimmune Therapeutics, Inc. | 3 | $73 |
| Sumitomo Pharma America, Inc. | 5 | $69 |
| Astellas Pharma US Inc | 3 | $67 |
| Edwards Lifesciences | 2 | $65 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Biogen | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Electronic Waveform Lab, Inc. | 1 | $30 |
| Amgen | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Currax Pharmaceuticals LLC | 2 | $24 |
| Bayer | 1 | $21 |
| Medtronic | 1 | $20 |
| Optos, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,470 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 36 | $43,479 |
| OzempicSemaglutide | 35 | $34,521 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $31,750 |
| EliquisApixaban | 31 | $31,088 |
| VraylarCariprazine Hcl | 14 | $23,484 |
| FarxigaDapagliflozin Propanediol | 19 | $21,064 |
| MyrbetriqMirabegron | 18 | $19,490 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $6,275 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,705 |
| Clomipramine Hcl | 11 | $4,474 |
| Levothyroxine Sodium | 229 | $2,097 |
| Atorvastatin Calcium | 160 | $1,626 |
| Bupropion XlBupropion Hcl | 41 | $1,479 |
| Fluticasone Propionate | 70 | $1,440 |
| Pantoprazole Sodium | 113 | $1,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $179 | $43,47936 claims |
| Novo NordiskOzempic | $201 | $34,52135 claims |
| GSKTrelegy Ellipta | $126 | $31,75034 claims |
| PfizerEliquis | $93 | $31,08831 claims |
| AstraZenecaFarxiga, Symbicort | $966 | $26,77036 claims |
| AbbVieVraylar | $1,680 | $23,48414 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $19,49018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.
Other physician assistant in Chandler
- Danielle ZitekChandler$24K
- Joan AltmanChandler$16K
- Carly HopkinsChandler$14K
- Julie SilverChandler$14K
- Emily RendaChandler$12K
- Jenna HiltonGilbert$637K
- Kara GoodingScottsdale$625K
- Ginna GranrothScottsdale$211K
- Nicole MaderaGlendale$128K
- Candace RyanGlendale$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.